Ken Griffin Intra Cellular Therapies, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$64.76 - $79.84 $3.67 Million - $4.53 Million	-56,700 Reduced 48.05%	61,300 $4.2 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $4.22 Million - $4.96 Million	65,600 Added 125.19%	118,000 $8.17 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $820,749 - $1.3 Million	17,700 Added 51.01%	52,400 $3.75 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $1.11 Million - $1.37 Million	21,400 Added 160.9%	34,700 $1.81 Million
Q2 2023 Aug 14, 2023	SELL	$54.67 - $66.44 $1.39 Million - $1.69 Million	-25,400 Reduced 65.63%	13,300 $842,000
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $30,659 - $39,893	700 Added 1.84%	38,700 $2.1 Million
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $453,921 - $560,835	-10,300 Reduced 21.33%	38,000 $2.01 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $2.12 Million - $2.98 Million	-49,600 Reduced 50.66%	48,300 $2.25 Million

402

90.5M

330K

306K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.35B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.